Ramy Younes

Turin, 10126, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 56 publications

Author Correction: Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.

Author Correction: Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.

Journal: Nature medicine

Published: August 26, 2026

Erratum: Noninvasive assessment of liver disease severity in NAFLD and T2D.

Erratum: Noninvasive assessment of liver disease severity in NAFLD and T2D.

Journal: Hepatology (Baltimore, Md.)

Published: July 17, 2026

Survodutide Once Weekly for the Treatment of Adults with Obesity.

Survodutide Once Weekly for the Treatment of Adults with Obesity.

Journal: The New England journal of medicine

Published: June 08, 2026

Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.

Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.

Journal: Nature medicine

Published: April 24, 2026

Metabolic dysfunction-associated steatohepatitis in the real world: clinical burden, disease progression, and risk stratification with non-invasive tests.

Metabolic dysfunction-associated steatohepatitis in the real world: clinical burden, disease progression, and risk stratification with non-invasive tests.

Journal: BMC gastroenterology

Published: January 19, 2026

Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH.

Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH.

Journal: Hepatology (Baltimore, Md.)

Published: December 17, 2025

Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH.

Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH.

Journal: Hepatology (Baltimore, Md.)

Published: December 17, 2025

The Future of Obesity Care: Exploring Synergies Between Metabolic Bariatric Surgery, Interventional Endoscopy and Pharmacotherapy.

The Future of Obesity Care: Exploring Synergies Between Metabolic Bariatric Surgery, Interventional Endoscopy and Pharmacotherapy.

Journal: Obesity surgery

Published: October 04, 2025

Thyroid Hormone Treatment for Hypercholesterolemia in Euthyroid Patients: Results From a European Survey of Thyroid Specialists.

Thyroid Hormone Treatment for Hypercholesterolemia in Euthyroid Patients: Results From a European Survey of Thyroid Specialists.

Journal: Clinical endocrinology

Published: March 08, 2025

Utilising national early warning score as a track and trigger mechanism in hospital-at-home care for acutely ill patients.

Utilising national early warning score as a track and trigger mechanism in hospital-at-home care for acutely ill patients.

Journal: Digital health

Published: December 13, 2024

Two Trials of Therapeutics for MASH with Liver Fibrosis. Reply.

Two Trials of Therapeutics for MASH with Liver Fibrosis. Reply.

Journal: The New England journal of medicine

Published: October 16, 2024

A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.

A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.

Journal: The New England journal of medicine

Published: June 07, 2024

Showing 1-12 of 56

Last Updated: 09/26/2026